People

WP leader of "Communication, Outreach and Dissemination" and Head of the Italian Joint Laboratory ProtEnz.

The research activity of Dr. B. Cobucci Ponzano concerns the study of the structure / function relationship of proteins and enzymes and of the mechanistic aspects related to hydrolysis and to enzymatic synthesis of glycosides. In particular, it deals with enzymes that modify carbohydrates (glycosidase) mainly from (hyper) thermophilic microorganisms, especially Archaea. In the lasts years, ...

Responsible of the Transnational Access of IBISBA1.0

Research Director at INRA Director Life Sciences at Toulouse White Biotechnology

Heleen De Wever obtained a PhD in Applied Biological Sciences in 1995. In 2001, she joined the Business Unit of Separation and Conversion Technology at VITO. She is currently leading VITO's biotechnology team which focusses on two main research lines. The first one is bioprocess intensification. Technological approaches include the combination of separation technology with bioconversions for high cell density fermentations, in-situ product recovery, enzyme immobilization and/or selective product ...

Advisor to the coordinator (Strategy and policy - public affairs)

PhD in Chemistry (Biochemistry). Research Professor at Consejo Superior de Investigaciones Científicas (CSIC) at Centro de Investigaciones Biológicas (CIB, CSIC) (Madrid, Spain) and at Instituto de Biología Integrativa de Sistemas (I2SysBIo, UV-CSIC) (Valencia, Spain)

Professor of Computer Science, Head of Node ELIXIR UK and ELIXIR ExCo for Interoperability, Coordinator of FAIRDOM Association e.V. Leads WP7 in the IBISBA1.0 which is providing support for data management and scientific workflows.

Co-leader of WP6 in the IBISBA 1.0 project. Leader of the Production host engineering Research team at VTT Technical Reseach Centre of Finland.

Head Chair of Systems & Synthetic Biology

I am trying to establish novel therapeutic avenues to cure a broad spectrum of rare diseases.

Each rare disease patient potentially benefitting from the therapeutic approach I propose carries a missense mutation in a glycoprotein gene. The mutation impairs fold of the mutate glycoprotein but does not abrogate its function (responsive mutation).

My idea is that modulators of Endoplasmic Reticulum glycoprotein folding Quality Control (ERQC) and/or of Endoplasmic Reticulum Associated Degradation ...